Ström & Gulliksson has assisted Swecure in patenting their technology for allergy prevention. The technology is based on scientific discoveries made by Agnes Wold, renowned Professor of Clinical Bacteriology at the Sahlgrenska Academy, and specialist in bacterial flora of the gut.
Ström & Gulliksson is a top-tier European patent firm offering start-to-finish patent management including searching, filing, prosecution, and validation of patent applications, strategic advice, opposition, appeal, and litigation assistance.
The Hygiene Hypothesis
One of Ström & Gulliksson’s clients is Swecure, a biotechnology company developing treatments for immunoregulatory disorders such as allergy and inflammatory bowel disease (IBD). Their patented technology for allergy prevention is based on scientific discoveries relating to allergies in children made by Agnes Wold and her research team at the Sahlgrenska University Hospital in the early 2000s.
Agnes adheres to the hygiene hypothesis which states that the more ‘hygienically’ children are raised, the more prone they are to developing allergies. Swecure therefore intends to prevent the development of allergies by stimulating the infant immune system during the first weeks after birth.
IP Related Business Advice
Though patent protection remains their core business, the business mindset of the attorneys at Ström & Gulliksson allows for a holistic approach towards their clients’ business models. ”Apart from drafting and prosecuting patent applications, we offer Swecure and other early stage companies IP related business advice that provides insight and valuable guidance to management teams,” says Dr Magnus Berglund, Partner at Ström & Gulliksson and head of their Life Science team.
Another important feature of Ström & Gulliksson is their close collaboration with Gulliksson Law Firm who is specialised in Intellectual Property Rights (IPR).
”The close collaboration gives our clients access to early stage qualified legal counselling at an affordable price. As an example, experienced legal input on licensing models is invaluable for start-ups and SMEs in the biotech sector not only for their IP strategy but also for their business model in general,” concludes Magnus.